# Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children

> **NCT01323972** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 327 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)

## Key facts

- **NCT ID:** NCT01323972
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-16
- **Primary completion:** 2011-11-22
- **Final completion:** 2012-05-04
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2018-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323972, "Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01323972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*